ANKRD13A: A Potential Drug Target and Biomarker (G88455)

Target Name: ANKRD13A

NCBI ID: G88455

ANKRD13A

ANKRD13A: A Potential Drug Target and Biomarker

Ankyrin subfamily A (ANKRD13A) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The ANKRD13A gene is located on chromosome 1p36 and encodes a protein known as ANKRD13A, which is a key regulator of the T-cell receptor (TCR), a critical immune system protein that plays a crucial role in fighting off infections and diseases.

In recent years, researchers have made significant progress in the study of ANKRD13A and its potential role in disease. Studies have shown that ANKRD13A is involved in the regulation of T-cell development, activation, and proliferation, and that it plays a key role in the development of autoimmune diseases such as rheumatoid arthritis (RA) and lupus.

Additionally, ANKRD13A has also been shown to be involved in the regulation of cancer cell growth and survival. Studies have shown that ANKRD13A can inhibit the growth of cancer cells in both human and animal models, and that it may be a useful target for cancer treatments.

Despite these promising findings, much more research is needed to fully understand the role of ANKRD13A in disease. One of the main challenges in studying ANKRD13A is its relatively high expression in many tissues, making it difficult to study its effects in specific cell types or contexts. Additionally, the complex interactions between ANKRD13A and other genes and molecules make it difficult to interpret its role in disease.

However, researchers are making efforts to overcome these challenges. By using techniques such as RNA interference, gene editing, and mass spectrometry, researchers are able to reduce the expression of ANKRD13A and study its effects in more specific contexts. This is providing new insights into the potential role of ANKRD13A in disease and the potential for it to be used as a drug target or biomarker.

In addition to its potential as a drug target, ANKRD13A is also being studied as a biomarker for various diseases. The ANKRD13A gene has been shown to be expressed in a variety of tissues and cells, including blood cells, tissues, and organs, making it a potential biomarker for a wide range of diseases.

Studies have shown that ANKRD13A is expressed in the majority of tissues and cells and that it is involved in the regulation of T-cell development, activation, and proliferation. This suggests that ANKRD13A may be a useful biomarker for diseases that are characterized by inflammation or T-cell dysregulation, such as RA, lupus, and a variety of autoimmune disorders.

In addition to its potential as a drug target and biomarker, ANKRD13A is also of interest to researchers because of its location on chromosome 1p36. This suggests that it may be involved in the regulation of chromosomal stability and that it may play a role in the development of genetic disorders.

Overall, the study of ANKRD13A is ongoing and has the potential to shed light on its role in disease and its potential as a drug target or biomarker. Further research is needed to fully understand its mechanisms of action and to develop effective treatments based on its potential.

Protein Name: Ankyrin Repeat Domain 13A

Functions: Ubiquitin-binding protein that specifically recognizes and binds 'Lys-63'-linked ubiquitin. Does not bind 'Lys-48'-linked ubiquitin. Positively regulates the internalization of ligand-activated EGFR by binding to the Ub moiety of ubiquitinated EGFR at the cell membrane

The "ANKRD13A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD13A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets